Literature DB >> 31801712

[Effect of Qingshen Granules on inflammation/hepcidin axis and iron metabolism in patients with renal anemia: a single-center, randomized controlled trial].

Lei Zhang1,2, Yiping Wang2, Hua Jin2, Dong Wang2, Ling Wei2, Kejun Ren2, Yanping Mao2.   

Abstract

OBJECTIVE: To evaluate the therapeutic effect of Qingshen Granules on renal anemia in patients with damp-heat syndrome and explore the mechanisms in light of inflammation/hepcidin axis and iron metabolism.
METHODS: Sixty patients with renal anemia and dampness-heat syndrome were randomized into control group (n=30) and treatment group (n=30). All the patients were given routine treatment, and the patients in the treatment group received additional treatment with Qingshen Granules (3 times a day). After 12 weeks of treatments, the patients were examined for changes in the integral value of TCM syndrome, serum creatinine (Scr), glomerular filtration rate (eGFR), hemoglobin (HGB), hematocrit (HCT), red blood cell (RBC) count, interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP), ferritin, growth differentiation factor-15 (GDF-15), serum iron (SI), total iron binding capacity (TIBC), transferrin saturation (TAST), soluble transferrin receptor (sTfR) and ferritin levels.
RESULTS: After the treatment, the scores of TCM syndrome were significantly improved in the treatment group and were better than those in the control group (P=0.000). Scr and eGFR were improved in both groups after the treatment. The levels of HGB, HCT and RBC were all improved in the two groups after treatment, and the improvements were more obvious in the treatment group (P=0.002, 0.002, and 0.017, respectively). The levels of IL-6, hs-CRP, hepcidine and GDF-15 were all lowered in the two groups after the treatment, and they were all significantly lower in the treatment group than in the control group (all P=0.000). The treatments increased the levels of SI and TAST in both of the groups, and compared with those in control group, the levels of TIBC, sTfR and ferritin were significantly lowered in the treatment group after the 12-week treatment (P=0.000).
CONCLUSIONS: Qingshen granules can effectively improve renal anemia in patients with damp-heat syndrome possibly by improving iron metabolism through alleviation of inflammation and reduction of hepcidine level.

Entities:  

Keywords:  Qingshen Granules; hepcidine; inflammation; iron metabolism; renal anemia

Mesh:

Substances:

Year:  2019        PMID: 31801712      PMCID: PMC6867959          DOI: 10.12122/j.issn.1673-4254.2019.10.04

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  18 in total

1.  Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease.

Authors:  Elisabeth Samouilidou; Konstantinos Pantelias; Dimitrios Petras; George Tsirpanlis; Joulia Bakirtzi; George Chatzivasileiou; Helen Tzanatos; Eirini Grapsa
Journal:  Ther Apher Dial       Date:  2013-09-30       Impact factor: 1.762

Review 2.  The Impact of Anemia Treatment on Health-Related Quality of Life in Patients With Chronic Kidney Disease in the Contemporary Era.

Authors:  Fredric O Finkelstein; Susan H Finkelstein
Journal:  Adv Chronic Kidney Dis       Date:  2019-07       Impact factor: 3.620

Review 3.  Growth differentiation factor 15 in erythroid health and disease.

Authors:  Toshihiko Tanno; Pierre Noel; Jeffery L Miller
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

4.  Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.

Authors:  Jilai Tian; Xiang Chen; Shengling Fu; Ruijie Zhang; Li Pan; Yang Cao; Xiaojuan Wu; Hui Xiao; Huey-Jen Lin; Hui-Wen Lo; Ying Zhang; Jiayuh Lin
Journal:  Breast Cancer Res Treat       Date:  2019-03-09       Impact factor: 4.872

Review 5.  Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease.

Authors:  Jolanta Malyszko; Jacek S Malyszko; Joanna Matuszkiewicz-Rowinska
Journal:  Expert Opin Ther Targets       Date:  2019-04-01       Impact factor: 6.902

6.  The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease.

Authors:  Takeshi Nakanishi; Tomoko Kimura; Takahiro Kuragano
Journal:  Contrib Nephrol       Date:  2019-04-16       Impact factor: 1.580

Review 7.  Hepcidin: A key regulator of iron.

Authors:  Syeda Saneela; Razia Iqbal; Ali Raza; Muhammad Fiaz Qamar
Journal:  J Pak Med Assoc       Date:  2019-08       Impact factor: 0.781

8.  Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates.

Authors:  Jason S Troutt; Anthony M Butterfield; Robert J Konrad
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

9.  GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.

Authors:  Courtney Tuegel; Ronit Katz; Mariam Alam; Zeenat Bhat; Keith Bellovich; Ian de Boer; Frank Brosius; Crystal Gadegbeku; Debbie Gipson; Jennifer Hawkins; Jonathan Himmelfarb; Wenjun Ju; Bryan Kestenbaum; Matthias Kretzler; Cassianne Robinson-Cohen; Susan Steigerwalt; Nisha Bansal
Journal:  Am J Kidney Dis       Date:  2018-06-14       Impact factor: 8.860

10.  Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.

Authors:  Nitya Nand; Kajaree Giri; Deepak Jain
Journal:  J Assoc Physicians India       Date:  2019-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.